Results of the randomized phase III trial of trabectedin (F) versus doxorubicin-based chemotherapy (DXCT) as First-line therapy in patients (pts) with translocation-related sarcoma (TRS).

被引：0
|
作者：
Hendifar, Andrew Eugene
Chawla, Sant P.
Leahy, Michael Gordon
Italiano, Antoine
Patel, Shreyaskumar
Santoro, Armando
Staddon, Arthur P.
Penel, Nicolas
Piperno-Neumann, Sophie
Demetri, George D.
Hayward, Larry
White, Jeff
Gouw, Launce G.
De Miguel, Bernardo
Lardelli, Pilar
Soto, Arturo
Nieto, Antonio
Blay, Jean-Yves
机构：
[1] Sarcoma Oncol Ctr, Santa Monica, CA USA
[2] Christie Hosp NHS Fdn Trust, Manchester, Lancs, England
[3] Inst Bergonie, Bordeaux, France
[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[5] Humanitas Canc Ctr, Rozzano, Italy
[6] Penn Hosp, Philadelphia, PA 19107 USA
[7] Ctr Oscar Lambert, Lille, France
[8] Inst Curie, Paris, France
[9] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA
[10] Western Gen Hosp, Edinburgh Canc Res UK Ctr, Edinburgh EH4 2XU, Midlothian, Scotland
[11] Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland
[12] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA
[13] PharmaMar, Madrid, Spain
[14] Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10517
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Biomarker Evaluation From the AVAGAST Randomized Phase III Trial
    Van Cutsem, Eric
    de Haas, Sanne
    Kang, Yoon-Koo
    Ohtsu, Atsushi
    Tebbutt, Niall C.
    Xu, Jian Ming
    Yong, Wei Peng
    Langer, Bernd
    Delmar, Paul
    Scherer, Stefan J.
    Shah, Manish A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (17) : 2119 - 2127
  • [32] Benmelstobart with Anlotinib plus Chemotherapy as First-line Therapy for ES-SCLC: A Randomized, Double-blind, Phase III Trial
    Cheng, Y.
    Yang, R.
    Chen, J.
    Zhang, W.
    Xie, C.
    Hu, Q.
    Zhou, N.
    Huang, C.
    Wei, S.
    Sun, H.
    Li, X.
    Yu, Y.
    Lai, J.
    Yang, H.
    Fang, H.
    Chen, H.
    Zhang, P.
    Gu, K.
    Wang, Q.
    Shi, J.
    Yi, T.
    Xu, X.
    Ye, X.
    Wang, D.
    Xie, C.
    Liu, C.
    Zheng, Y.
    Lin, D.
    Zhuang, W.
    Lu, P.
    Yu, G.
    Li, J.
    Gu, Y.
    Li, B.
    Wu, R.
    Jiang, O.
    Wang, Z.
    Wu, G.
    Lin, H.
    Zhong, D.
    Xu, Y.
    Shu, Y.
    Wu, D.
    Chen, X.
    Wang, J.
    Wang, M.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S44 - S44
  • [33] Phase III randomized trial of sunitinib malate versus interferon-alfa as first-line systemic therapy for patients with metastatic renal cell carcinoma
    Rixe, O.
    Hutson, T. E.
    Tomczak, P.
    Michaelson, M. D.
    Bukowski, R. M.
    Oudard, S.
    Negrier, S.
    Kim, S. T.
    Chen, I.
    Figlin, R. A.
    Motzer, R. J.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2007, 6 (02) : 237 - 237
  • [34] Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA
    Oudard, Stephane
    Fizazi, Karim
    Sengelov, Lisa
    Daugaard, Gedske
    Saad, Fred
    Hansen, Steinbjorn
    Hjalm-Eriksson, Marie
    Jassem, Jacek
    Thiery-Vuillemin, Antoine
    Caffo, Orazio
    Castellano, Daniel
    Mainwaring, Paul N.
    Bernard, John
    Shen, Liji
    Chadjaa, Mustapha
    Sartor, Oliver
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (28) : 3189 - +
  • [35] MAIN-CAV: Phase III randomized trial of maintenance cabozantinib and avelumab versus avelumab after first-line platinum-based chemotherapy in patients (pts) with metastatic urothelial cancer (mUC; Alliance A032001).
    Gupta, Shilpa
    Ballman, Karla V.
    Galsky, Matt D.
    Morris, Michael J.
    Sridhar, Srikala S.
    Chen, Ronald C.
    Chan, Timothy An-Thy
    Wen, Yujia
    Grivas, Petros
    Tan, Alan
    Baghaie, Shiva
    Rosenberg, Jonathan E.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [36] Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer:: A randomized phase III study
    Saltz, Leonard B.
    Clarke, Stephen
    Diaz-Rubio, Eduardo
    Scheithauer, Werner
    Figer, Arie
    Wong, Ralph
    Koski, Sheryl
    Lichinitser, Mikhail
    Yang, Tsai-Shen
    Rivera, Fernando
    Couture, Felix
    Sirzen, Florin
    Cassidy, Jim
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (12) : 2013 - 2019
  • [37] Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial
    Honecker, Friedemann
    Harbeck, Nadia
    Schnabel, Claudia
    Wedding, Ulrich
    Waldenmaier, Dirk
    Saupe, Steffen
    Jaeger, Elke
    Schmidt, Marcus
    Kreienberg, Rolf
    Mueller, Lothar
    Otremba, Burkhard
    Dorn, Julia
    Warm, Mathias
    Al-Batran, Salah-Eddin
    de Wit, Maike
    [J]. JOURNAL OF GERIATRIC ONCOLOGY, 2018, 9 (02) : 163 - 169
  • [38] A randomized phase III trial on Pembrolizumab Alone versUs pembrolizumab-chemotherapy in first LInE NSCLC (PAULIEN), results of the interim analysis
    Houda, I.
    Ulas, E. B.
    Hashemi, S. M. S.
    Becker, A.
    Daniels, H. M. A.
    Tarasevych, S.
    Looysen, E.
    Kunst, P.
    Moons-Pasic, A.
    Thonissen, N.
    van Haarst, J. M. W.
    van Tilburg, P.
    van der Maat, B.
    Barlo, N.
    Disselhorst, M.
    van Diepen, V.
    Tiemessen, M.
    van Laren, M.
    Veltman, J.
    Bahce, I.
    [J]. ANNALS OF ONCOLOGY, 2023, 34
  • [39] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Yoshito Komatsu
    Chikashi Ishioka
    Ken Shimada
    Yasuhide Yamada
    Makio Gamoh
    Atsushi Sato
    Tatsuro Yamaguchi
    Satoshi Yuki
    Satoshi Morita
    Shin Takahashi
    Rei Goto
    Minoru Kurihara
    [J]. BMC Cancer, 15
  • [40] Study protocol of the TRICOLORE trial: a randomized phase III study of oxaliplatin-based chemotherapy versus combination chemotherapy with S-1, irinotecan, and bevacizumab as first-line therapy for metastatic colorectal cancer
    Komatsu, Yoshito
    Ishioka, Chikashi
    Shimada, Ken
    Yamada, Yasuhide
    Gamoh, Makio
    Sato, Atsushi
    Yamaguchi, Tatsuro
    Yuki, Satoshi
    Morita, Satoshi
    Takahashi, Shin
    Goto, Rei
    Kurihara, Minoru
    [J]. BMC CANCER, 2015, 15
12345